The influence of conjugation variables on the design and immunogenicity of a glycoconjugate vaccine against Salmonella Typhi

Determination of free polysaccharide in Vi glycoconjugate vaccine against typhoid fever

(2017) C. Giannelli et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Sugar-Protein Connectivity Impacts on the Immunogenicity of Site-SelectiveSalmonellaO-Antigen Glycoconjugate Vaccines

(2015) Giuseppe Stefanetti et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Structural correlates of carrier protein recognition in tetanus toxoid-conjugated bacterial polysaccharide vaccines

(2015) Kay Lockyer et al.   VACCINE

A systematic analysis of DMTMM vs EDC/NHS for ligation of amines to Hyaluronan in water

(2014) Matteo D’Este et al.   CARBOHYDRATE POLYMERS

Vaccines against invasive Salmonella disease

(2014) Calman A MacLennan et al.   Human Vaccines & Immunotherapeutics

Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment

(2014) Vittal Mogasale et al.   Lancet Global Health

Designing Vaccines for the Twenty-First Century Society

(2014) Oretta Finco et al.   Frontiers in Immunology

Development of Vi conjugate – a new generation of typhoid vaccine

(2013) Shousun Chen Szu   Expert Review of Vaccines

Comparison of EDC and DMTMM efficiency in glycoconjugate preparation

(2013) Pavol Farkaš et al.   INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials

(2013) Zulfiqar A Bhutta et al.   LANCET INFECTIOUS DISEASES

The Capsular Polysaccharide Vi from Salmonella Typhi Is a B1b Antigen

(2012) J. L. Marshall et al.   JOURNAL OF IMMUNOLOGY

Biochemical and biological characteristics of cross-reacting material 197 (CRM197), a non-toxic mutant of diphtheria toxin: Use as a conjugation protein in vaccines and other potential clinical applications

(2011) Michael Bröker et al.   BIOLOGICALS

Evaluation of the Immunogenicity and Biological Activity of theCitrobacter freundiiVi-CRM197Conjugate as a Vaccine forSalmonella entericaSerovar Typhi

(2011) Simona Rondini et al.   Clinical and Vaccine Immunology

The Vi Conjugate Typhoid Vaccine Is Safe, Elicits Protective Levels of IgG Anti-Vi, and Is Compatible with Routine Infant Vaccines

(2011) Vu Dinh Thiem et al.   Clinical and Vaccine Immunology

The design of semi-synthetic and synthetic glycoconjugate vaccines

(2011) Paolo Costantino et al.   Expert Opinion on Drug Discovery

Safety, Immunogenicity and Dose Ranging of a New Vi-CRM197 Conjugate Vaccine against Typhoid Fever: Randomized Clinical Testing in Healthy Adults

(2011) Pierre van Damme et al.   PLoS One

Physico-chemical properties of Salmonella typhi Vi polysaccharide–diphtheria toxoid conjugate vaccines affect immunogenicity

(2011) So Jung An et al.   VACCINE

Production of a conjugate vaccine for Salmonella enterica serovar Typhi from Citrobacter Vi

(2011) F. Micoli et al.   VACCINE

Vi-CRM197 as a new conjugate vaccine against Salmonella Typhi

(2010) F. Micoli et al.   VACCINE

Physical and Chemical Characterization and Immunologic Properties of Salmonella enterica Serovar Typhi Capsular Polysaccharide-Diphtheria Toxoid Conjugates

(2009) C. Cui et al.   Clinical and Vaccine Immunology